

Daniele Raggi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9147108/daniele-raggi-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

101
papers

1,723
citations

22
h-index

37
g-index

108
ext. papers

2,351
ext. citations

4.2
avg, IF

4.34
L-index

#	Paper	IF	Citations
101	Von Hippel-Lindau disease-associated renal cell carcinoma: a call to action. <i>Current Opinion in Urology</i> , 2022 , 32, 31-39	2.8	0
100	A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022 , 40, 10.e1-10.e6	2.8	2
99	Impact of Novel Hormonal Therapy on Cognitive Function: Essential to Measure, Difficult to Present.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2200092	2.2	2
98	The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2021 , 4, 829-833	6.7	8
97	Bladder-sparing combination treatments for muscle-invasive bladder cancer: A plea for standardized assessment and definition of clinical trials endpoints. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 40, 37-37	2.8	
96	Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma. <i>European Urology Oncology</i> , 2021 , 4, 802-810	6.7	5
95	Prognostic Role of Early Interim Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced Seminoma Undergoing Standard Treatment. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 237-245.e2 ²	3.3	2
94	Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy. <i>European Urology Focus</i> , 2021 , 7, 1092-1099	5.1	1
93	The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3). <i>World Journal of Urology</i> , 2021 , 39, 3407-3414	4	3
92	Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 159, 103241	7	5
91	Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 48-53	9.7	15
90	Contemporary Treatment Patterns and Outcomes for Patients with Penile Squamous Cell Carcinoma: Identifying Management Gaps to Promote Multi-institutional Collaboration. <i>European Urology Oncology</i> , 2021 , 4, 121-123	6.7	5
89	[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 235.e15-235.e21	2.8	3
88	Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). <i>Clinical Medicine Insights: Oncology</i> , 2021 , 15, 11795549211021667	1.8	1
87	Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma. <i>Journal of Urology</i> , 2021 , 205, 414-419	2.5	1
86	Renal function outcomes in patients with muscle-invasive bladder cancer treated with neoadjuvant pembrolizumab and radical cystectomy in the PURE-01 study. <i>International Journal of Cancer</i> , 2021 , 149, 186-190	7.5	1
85	The Pros and Cons of Machination of Medicine in Genitourinary Oncology Practice. <i>Bladder Cancer</i> , 2021 , 1-5	1	

84	Neoadjuvant Immunotherapy: The Next Gold Standard Before Radical Surgery for Urothelial Cancer. <i>European Urology Open Science</i> , 2021 , 30, 34-36	0.9	1
83	Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab. <i>European Urology</i> , 2021 , 80, 149-159	10.2	5
82	Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard. <i>European Urology Oncology</i> , 2021 , 5, 1-1	6.7	2
81	Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?. <i>European Urology</i> , 2021 , 80, 319-322	10.2	5
80	Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 734.e11-734.e17	2.8	2
79	Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 631-641	2.8	3
78	Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study.. <i>Clinical Genitourinary Cancer</i> , 2021 ,	3.3	1
77	Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study. <i>European Urology Oncology</i> , 2020 , 4, 1001-1001	6.7	9
76	Optimising the selection of candidates for neoadjuvant chemotherapy amongst patients with node-positive penile squamous cell carcinoma. <i>BJU International</i> , 2020 , 125, 867-875	5.6	10
75	Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2020 , 77, 701-710	10.2	66
74	Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. <i>European Urology</i> , 2020 , 77, 548-556	10.2	19
73	Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer. <i>European Urology</i> , 2020 , 77, 269-276	10.2	24
72	Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. <i>European Urology</i> , 2020 , 77, 439-446	10.2	119
71	Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. <i>European Urology</i> , 2020 , 77, 636-643	10.2	48
70	Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm?. <i>European Urology Oncology</i> , 2020 ,	6.7	9
69	Identifying an optimal lymph node yield for penile squamous cell carcinoma: prognostic impact of surgical dissection. <i>BJU International</i> , 2020 , 125, 82-88	5.6	10
68	Erdafitinib for the treatment of urothelial cancer. <i>Expert Review of Anticancer Therapy</i> , 2019 , 19, 835-846	5.5	6
67	Nomogram-based prediction of overall survival after regional lymph node dissection and the role of perioperative chemotherapy in penile squamous cell carcinoma: A retrospective multicenter study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 531.e7-531.e15	2.8	19

66	Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies. <i>Cancers</i> , 2019 , 11,	6.6	10
65	Role of Neoadjuvant and Adjuvant Chemotherapy in Penile Cancer 2019 , 845-850		
64	Comparison of Fibroblast Growth-factor Receptor Gene Alterations at the DNA versus Messenger RNA Level in Advanced Urothelial Cancer: Insights for Clinical Research. <i>European Urology Focus</i> , 2019 , 5, 689-692	5.1	1
63	An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis. <i>European Urology</i> , 2019 , 75, 201-203	10.2	40
62	Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort. <i>European Urology Focus</i> , 2019 , 5, 853-856	5.1	5
61	Secondary malignancies after high-dose chemotherapy in germ cell tumor patients: a 34-year retrospective study of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2018 , 53, 722-728	4.4	4
60	Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e961-e967	3.3	12
59	Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure. <i>European Journal of Cancer</i> , 2018 , 96, 128-130	7.5	5
58	Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial Carcinoma: Insights for Clinical Research. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e403-e410	3.3	5
57	Immunotherapy for metastatic urothelial carcinoma: status quo and the future. <i>Current Opinion in Urology</i> , 2018 , 28, 1-7	2.8	5
56	First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study. <i>BJU International</i> , 2018 , 121, 348-356	5.6	47
55	Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 8.e1-8.e8	2.8	6
54	Laparoscopic Retroperitoneal Lymph Node Dissection for Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Safety and Efficacy Analyses at a High Volume Center. <i>Journal of Urology</i> , 2018 , 199, 741-747	2.5	10
53	Nivolumab and its use in the second-line treatment of metastatic urothelial cancer. <i>Future Oncology</i> , 2018 , 14, 2683-2690	3.6	0
52	Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3353-3360	2.2	265
51	Role of Neoadjuvant and Adjuvant Chemotherapy in Penile Cancer 2018 , 1-6		
50	Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. <i>Journal of Urology</i> , 2018 , 200, 1207-1214	2.5	10
49	Etoposide, Methotrexate, and Dactinomycin Alternating With Cyclophosphamide and Vincristine (EMACO) for Male Patients With HCG-expressing, Chemoresistant Germ Cell Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017 , 40, 60-65	2.7	2

48	Treatment of Carcinoma In Situ of the Glans Penis With Topical Imiquimod Followed by Carbon Dioxide Laser Excision. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e483-e487	3-3	5
47	Association of an aurora kinase a (AURKA) gene polymorphism with progression-free survival in patients with advanced urothelial carcinoma treated with the selective aurora kinase a inhibitor alisertib. <i>Investigational New Drugs</i> , 2017 , 35, 524-528	4-3	8
46	From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 509-512.e9	3-3	1
45	Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial. <i>Annals of Oncology</i> , 2017 , 28, 1346-1351	10-3	27
44	Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 548-555.e3 ²⁴	3-3	24
43	Effect of Bleomycin Administration on the Development of Pulmonary Toxicity in Patients With Metastatic Germ Cell Tumors Receiving First-Line Chemotherapy: A Meta-Analysis of Randomized Studies. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 213-220.e5	3-3	19
42	Salvage High-Dose Chemotherapy for Relapsed Pure Seminoma in the Last 10 Years: Results From the European Society for Blood and Marrow Transplantation Series 2002-2012. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 163-167	3-3	2
41	A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 306-312.e3	3-3	20
40	Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 23-30.e2	3-3	36
39	Administration of high-dose chemotherapy with stem cell support in patients 40 years of age or older with advanced germ cell tumours: a retrospective study from the European Society for Blood and Marrow Transplantation database. <i>Bone Marrow Transplantation</i> , 2017 , 52, 1218-1220	4-4	3
38	A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 323-30	3-3	45
37	Panitumumab Treatment for Advanced Penile Squamous Cell Carcinoma When Surgery and Chemotherapy Have Failed. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 231-6	3-3	30
36	The Changing Landscape of Intermediate- and Poor-Risk Germ Cell Tumors: Do We Need to Reclassify Patients With Metastatic Germ Cell Tumors?. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 1-4	3-3	3
35	Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients. <i>Journal of Endourology</i> , 2016 , 30, 1112-1119	3-3	13
34	Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, e81-90	3-3	4
33	Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration. <i>Journal of Urology</i> , 2016 , 196, 95-100	2-5	41
32	Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party. <i>Bone Marrow Transplantation</i> , 2016 , 51, 384-90	4-4	6
31	An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer. <i>Investigational New Drugs</i> , 2016 , 34, 236-42	4-3	20

30	Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. <i>Annals of Oncology</i> , 2016 , 27, 49-61	10.3	74
29	The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016 , 69, 624-633	10.2	15
28	Clinical Significance of Early Changes in Circulating Tumor Cells from Patients Receiving First-Line Cisplatin-Based Chemotherapy for Metastatic Urothelial Carcinoma. <i>Bladder Cancer</i> , 2016 , 2, 395-403	1	11
27	Immunotherapy advances in uro-genital malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 105, 52-64	7	16
26	Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 494-498	3.3	1
25	Interim (18)F-Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Response to Cisplatin, Etoposide, and Bleomycin Chemotherapy for Metastatic Seminoma: Clinical Value and Future Directions. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 249-54	3.3	9
24	Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 261-264.e4	3.3	19
23	Prognostic Factors of Adjuvant Taxane, Cisplatin, and 5-Fluorouracil Chemotherapy for Patients With Penile Squamous Cell Carcinoma After Regional Lymphadenectomy. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 518-523	3.3	22
22	Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 332.e19-24	2.8	12
21	Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 385-391.e1	3.3	4
20	Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. <i>Annals of Oncology</i> , 2015 , 26, 657-668	10.3	39
19	Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2015 , 7, 152-61	3.2	17
18	Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 171-7.e1	3.3	8
17	High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study. <i>Annals of Oncology</i> , 2015 , 26, 167-172	10.3	15
16	A prognostic model including pre- and postsurgical variables to enhance risk stratification of primary mediastinal nonseminomatous germ cell tumors: the 27-year experience of a referral center. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 87-93.e1	3.3	16
15	Quality of life and pain control following laparoscopic retroperitoneal lymph node dissection in early-stage nonseminoma. <i>Tumori</i> , 2015 , 101, 650-6	1.7	4
14	Relationship between lymph node ratio and cancer-specific survival in a contemporary series of patients with penile cancer and lymph node metastases. <i>BJU International</i> , 2015 , 116, 727-33	5.6	19
13	Postchemotherapy lymphadenectomy in patients with metastatic urothelial carcinoma: long-term efficacy and implications for trial design. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 80-86.e1	3.3	16

12	Clinical outcome in testicular sex cord stromal tumors: testis sparing vs. radical orchiectomy and management of advanced disease. <i>Urology</i> , 2015 , 85, 402-6	1.6	35
11	Predictors of CD34+ cell mobilization and collection in adult men with germ cell tumors: implications for the salvage treatment strategy. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 196-202.e1	3.3	2
10	PF-03446962, a fully-human monoclonal antibody against transforming growth-factor [TGF] receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. <i>Investigational New Drugs</i> , 2014 , 32, 555-60	4.3	38
9	Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 433-9	3.3	23
8	Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomes. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 63-69.e1	3.7	24
7	The relationship between characteristics of inguinal lymph nodes and pelvic lymph node involvement in penile squamous cell carcinoma: a single institution experience. <i>Journal of Urology</i> , 2014 , 191, 977-82	2.5	51
6	Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy. <i>British Journal of Cancer</i> , 2014 , 110, 26-33	8.7	16
5	Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 203-209.e1	3.3	14
4	Activity of pazopanib in chemo-resistant patients with germ cell tumors (GCT): First results of the open-label, single-group, phase II PAZOTEST-01 trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 376-376	2.2	5
3	Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes. <i>Annals of Oncology</i> , 2013 , 24, 2887-92	10.3	13
2	Persistent CD30 expression by embryonal carcinoma in the treatment time course: prognostic significance of a worthwhile target for personalized treatment. <i>Journal of Urology</i> , 2013 , 190, 1919-24	2.5	26
1	Pembrolizumab as Neoadjuvant Therapy Preceding Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Group, Phase 2 Study. <i>SSRN Electronic Journal</i> ,	1	9